Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/222390
The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
Plasmablastic lymphoma (PBL) is an uncommon and aggressive B-cell lymphoma with a poor prognosis. Some studies have described genetic alterations in PBL, but its transcriptome has been scarcely studied, and molecular mechanisms driving lymphomagenesis remain poorly understood. Our goal was to delineate transcriptomic profiles to identify potential biomarkers for novel targeted therapy in PBL. RNA sequencing uncovered an enrichment of cell cycle-related genes, including MYC and E2F targets, and genes involved in G2/M checkpoint in PBL. Microarray analyses discovered 2 microRNA expression signatures depending on the presence of MYC translocation. Interestingly, miR-150-5p was downregulated, whereas E2F3 and BIRC5 (survivin), a cell cycle activator and an antiapoptotic regulator, respectively, were upregulated. Increasing miR-150-5p in PBL-1 cells induced G1 cell cycle arrest, suppressed proliferation by transcriptionally repressing E2F3, and promoted apoptosis by the downregulation of BIRC5. Interestingly, the miR-150-5p tumor suppressor activity was diminished in E2F3-knockdown cells. The combined inhibition of E2F3 and survivin attenuated lymphomagenesis in PBL cells and suppressed tumor growth in a chorioallantoic membrane-derived xenograft model of PBL. Overall, our study highlights the pivotal role of the miR-150-5p/E2F3/survivin axis in boosting PBL lymphomagenesis and unveils new therapeutic targets for this lymphoma.
Matèries (anglès)
Citació
Citació
VERDÚ BOU, Miriam, BAPTISTA, Maria joao, LIMA RIBEIRO, Marcelo, MÉNDEZ LÓPEZ, Aleix, PROFITÓS PELEJÀ, Núria, FRONTZEK, Fabian, ROUÉ, Gaël, MATE, José l., PELLICER, Mireia, ABRISQUETA, Pau, CASTELLVÍ, Josep, BASTOS OREIRO, Mariana, MENÁRGUEZ, Javier, ALCOCEBA, Miguel, GONZÁLEZ BARCA, Eva, CLIMENT, Fina, SALAR, Antonio, SANCHO, Juan manuel, STAIGER, Annette m., OTT, German, ANAGNOSTOPOULOS, Ioannis, ESTELLER, Manel, LENZ, Georg, TAPIA, Gustavo, NAVARRO, José tomás. The role of miR-150-5p/E2F3/survivin axis in the pathogenesis of plasmablastic lymphoma and its therapeutic potential. _Blood Advances_. 2025. Vol. 9, núm. 12, pàgs. 2953-2967. [consulta: 9 de gener de 2026]. ISSN: 2473-9537. [Disponible a: https://hdl.handle.net/2445/222390]